A Comprehensive Review on Alzheimer’s Disease its Pathogenesis, Epidermiology, Diagnostics and Treatment

Ajinkya Balasaheb Chavan; Sachin Rangrao Patil; Ansar Mansur Patel; Shweta Vijay Chaugule; Sayali Krishnat Gharal

doi:10.55544/jrasb.2.4.8

Authors

Ajinkya Balasaheb Chavan Head of Department, Sant Gajanan Maharaj College of Pharmacy, Mahagaon, Dist-Kolhapur Maharashtra, INDIA.
Sachin Rangrao Patil Head of Department, Sant Gajanan Maharaj Rural Pharmacy College, Mahagaon, Dist-Kolhapur Maharashtra, INDIA.
Dr. Ansar Mansur Patel Principal, Sant Gajanan Maharaj Rural Pharmacy College, Mahagaon, Dist-Kolhapur Maharashtra, INDIA.
Shweta Vijay Chaugule Lecturer, Sant Gajanan Maharaj College of Pharmacy, Mahagaon, Dist-Kolhapur Maharashtra, INDIA.
Sayali Krishnat Gharal Lecturer, Sant Gajanan Maharaj Rural Pharmacy College, Mahagaon, Dist-Kolhapur Maharashtra, INDIA.

DOI:

https://doi.org/10.55544/jrasb.2.4.8

Keywords:

Alzheimer disease, Diagnosis, Pathogenesis, Therapeutic effect

Abstract

The global impact of Alzheimer's disease (AD) is significant. The current prevalence of Major Neurocognitive Disorder is estimated to affect approximately 44 million individuals. Presently, the United States harbors a population of approximately 6.2 million individuals who are afflicted by Alzheimer's disease (AD) dementia. It is of significance to highlight that mortality associated with Alzheimer's disease (AD) exceeds the combined mortality rates of both breast cancer and prostate cancer. Based on the findings of the National Institute on Aging, the frequency of Alzheimer's disease (AD) exhibits a twofold rise every five years subsequent to attaining the age of 65. Furthermore, with the ongoing process of population aging, an increasingly substantial portion of the population is affected by this particular condition. Based on forecasts, it is anticipated that the United States will experience a financial impact of $355 billion in 2021 as a result of Alzheimer's disease (AD).

Furthermore, same projections indicate that this amount is expected to increase significantly to over $1.5 trillion by the year 2050. As a result, this would place a significant financial strain on the country. Alzheimer's disease (AD) is a neurodegenerative condition that is distinguished by the existence of extracellular amyloid β (Aβ) plaques and intracellular neurofibrillary tangles consisting of hyperphosphorylated τ-protein. The aforementioned abnormal characteristics primarily present themselves inside the cortical and limbic regions of the human brain. The aforementioned ailment is characterized by the presence of memory impairment and a progressive deterioration of neurocognitive abilities. The atypical division of amyloid precursor protein (APP) by β-secretases and γ-secretases leads to the production of Aβ40 and Aβ42 individual molecules, which then undergo the process of oligomerization and aggregation, finally culminating in the formation of senile plaques. The aforementioned disease is additionally aggravated by pathogenic microorganisms, including the human immunodeficiency virus (HIV).

Moreover, within the framework of disease pathophysiology, the presence of heightened amounts of Aβ peptides within the central nervous system induces the infiltration of microglial cells. Presently, there exists a notable focus within the realm of scientific inquiry on gaining a comprehensive understanding of the pathological nature of Alzheimer's disease (AD) by means of exploring diverse pathways.

These mechanisms include the abnormal metabolism of tau proteins, the presence of β-amyloid, the inflammatory response, as well as the damage caused by cholinergic dysfunction and free radicals. The ultimate objective of this research is to develop efficacious treatments that can effectively halt or alter the progression of AD. The present study provides an analysis of the pathophysiological mechanisms underlying Alzheimer's disease, as well as an examination of the diagnostic methods employed in its identification. Furthermore, the review explores the many therapy modalities now utilized in managing this neurodegenerative disorder.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

De-Paula V.J., Radanovic M., Diniz B.S., Forlenza O.V. Alzheimer’s disease. Sub-Cell. Biochem. 2012;65:329–352. doi: 10.1007/978-94-007-5416-4_14.

Cipriani G., Dolciotti C., Picchi L., Bonuccelli U. Alzheimer and his disease: A brief history. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 2011;32:275–279. doi: 10.1007/s10072-010-0454-7.

Blass J.P. Alzheimer’s disease. Dis. A Mon. Dm. 1985;31:1–69. doi: 10.1016/0011-5029(85)90025-2.

Terry R.D., Davies P. Dementia of the Alzheimer type. Annu. Rev. Neurosci. 1980;3:77–95. doi: 10.1146/annurev.ne.03.030180.000453.

Rathmann K.L., Conner C.S. Alzheimer’s disease: Clinical features, pathogenesis, and treatment. Drug Intell. Clin. Pharm. 1984;18:684–691. doi: 10.1177/106002808401800902.

Henry W, Querfurth H, LaFerla F. Mechanisms of disease Alzheimer’s disease. New Engl J Med. 2010;362:329–344. doi: 10.1056/NEJMra0909142

Alzheimer’s A. 2015 Alzheimer‘s disease facts and figures. Alzheimer‘S Dementia. 2015;11(3):332. doi: 10.1016/j.jalz.2015.02.003

Goedert M. Alzheimer’s and Parkinson’s diseases: the prion concept in relation to assembled Aβ, tau, and α-synuclein. Science. 2015;349(6248):1255555. doi: 10.1126/science.1255555

Lombardi, G., Crescioli, G., Cavedo, E., Lucenteforte, E., Casazza, G., Bellatorre, A.-G., et al.Filippini, G. (2020, March 2). Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer’s disease in people with mild cognitive impairment. Cochrane Database Syst Rev, 3(3), CD009628. 10.1002/14651858.CD009628.pub2

Chance, S. A., Clover, L., Cousijn, H., Currah, L., Pettingill, R., & Esiri, M. M. (2011, August). Microanatomical correlates of cognitive ability and decline: Normal ageing, MCI, and Alzheimer’s disease. Cereb Cortex, 21(8), 1870–1878. 10.1093/cercor/bhq264

van Veluw, S. J., Sawyer, E. K., Clover, L., Cousijn, H., De Jager, C., Esiri, M. M., & Chance, S. A. (2012, October). Prefrontal cortex cytoarchitecture in normal aging and Alzheimer’s disease: A relationship with IQ. Brain Structure & Function, 217(4), 797–808. 10.1007/s00429-012-0381-x

Hanseeuw, B. J., Betensky, R. A., Jacobs, H. I. L., Schultz, A. P., Sepulcre, J., Becker, J. A., et al.Johnson, K. (2019, August 1). Association of amyloid and tau with cognition in preclinical Alzheimer disease: A longitudinal study. JAMA Neurology, 76(8), 915–924. 10.1001/jamaneurol.2019.1424

Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., . . .. Zetterberg, H., & the Amyloid Biomarker Study Group. (2015, May 19). Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA, 313(19), 1924–1938.

Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., et al.Hansson, O. (2020, August 25). Discriminative accuracy of plasma phospho-tau217 for Alzheimer Disease vs other neurodegenerative disorders. JAMA, 324(8), 772–781. 10.1001/jama.2020.12134

Landhuis, E. (2021). Detecting Alzheimer’s gets easier with a simple blood test. Scientific American, 3(1). Retrieved from https://www.scientificamerican.com/article/detecting-alzheimers-gets-easier-with-a-simple-blood-test/

Fandos, N., Pérez-Grijalba, V., Pesini, P., Olmos, S., Bossa, M., Villemagne, V. L., . . .. Sarasa, M., & the AIBL Research Group. (2017, September 12). Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals. Alzheimers Dement (Amst), 8, 179–187.

Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., et al.Hansson, O. (2020, March). Plasma P-tau181 in Alzheimer’s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nature Medicine, 26(3), 379–386. 10.1038/s41591-020-0755-1

American Psychiatric Association. Practice Guidelines for the treatment of patients with Alzheimer's Disease and other dementias of late life. Am J Psychiatry. 1997;154(suppl 5):1–39.

Mittleman MS., Feris SH., Shulman E., et al. A family intervention to delay nursing home placement of patients with Alzheimer's disease: a randomized controlled trial. JAMA. 1996;276:1725–1731.

Stern Y., Tang MX., Albert M., et al. Predicting time to nursing home care and death in individuals with Alzheimer's disease. JAMA. 1997;277:806–812.

Schachter AS., Davis KL. Alzheimer's disease. Curr Treat Options Neurol. 2000;2:51–60.

Schachter AS., Davis KL. Guidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer's disease. CNS Drugs. 1999;11:281–288.

Rogers SL., Doody RS., Mohs RC., Friedhoff LZT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998;158:1021–1031.

Shintani EY., Uchida KM. Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. Am J Health Syst Pharm. 1998;54:2805–2810.

Rogers SL., Farlow MR., Doody RS., et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998;50:136–145.

Rogers SL., Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicenter open label extension study. Eur Neuropsychopharmacol. 1998;8:67–75.

Burns A., Rossor M., Hecker J., Gautier S., et al. The effects of donepezil in Alzheimer's disease: results form a multinational trial. Dement Geriatr Cogn Disord. 1999;10:237–244.

Samuels SC., Davis KL. A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease. Drug Saf. 1997;16:66–77.

Davis KL., Thai LJ., Gamzu ER., et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. N Engl J Med. 1992;327:1253–1259.

Gracon SI., Knapp MJ., Berghoff WG., et al. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis Assoc Disord. 1998;12:93–101.

Knapp MJ., Knopman DS., Solomon PR., Pendlebury WW., Davis CS., Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA. 1994;271:985–991.

Thomsen T., Bickel U., Fischer JP., et al. Galanthamine hydrobromide is a long-term treatment of Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase. J Pharmacol Exp Ther. 1995;274:767–770.

Parys W., Pontecorvo M J. Treatment of Alzheimer's disease with galanthamine, a compound with a dual mechanism of action. Janssen Research Foundation. 1998 Data on file

Bores GM., Huger FP., Petko W., et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther. 1998;277:728–738.

Sramek JJ., Anand R., Wardle TS., et al. Safety/tolerability trial of SDZ ENA713 in patients with probable Alzheimer's disease. Life Sci. 1996;58:1201–1207.

Nair NP., Amin M., Holm P., et al. Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo. J Affect Disord. 1995;33:1–9.

Schweitzer E., Rickels K., Hassman H., et al. Buspirone and imipramine for the treatment of major depression in the elderly. J Clín Psychiatry. 1998;59:175–183.

Taragano FE., Lyketsos CG., Mangone CA., Allegri RF., Comesana-Diaz E. A double-blind, randomized, fixed-dose trial of fluoxetine vs amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics. 1997;38:246–252.

Katona CL., Hunter BN., Bray J. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry. 1998;13:100–108.

Olafsson K., Jorgensen S., Jensen HV., Bille A., Arup P., Andersen J. Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebo-controlled study. Acta Psychiatr Scand. 1992;85:453–456.